Ovarian cancer biomarkers as diagnostic triage tests

References

• National Cancer Institute. Surveillance Epidemiology and End results. SEER Stat Fact Sheets: Ovary. Available from: http://seer.cancer.gov/statfacts/html/ovary.html. Accessed January 11, 2013.
   Google Scholar
• Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–46.
   PubMed Web of Science ®Google Scholar
• Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012;22(10 Suppl 1):S5–S8.
   Google Scholar
• Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–287.
   PubMed Web of Science ®Google Scholar
• Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99(2):447–461.
   PubMed Web of Science ®Google Scholar
• Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol. 2006;49(3):448–458.
   PubMed Web of Science ®Google Scholar
• Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol. 2007;110(4):841–848.
   PubMed Web of Science ®Google Scholar
• Maggino T, Gadducci A, D’Addario V et al. Prospective multicenter study on CA125 in postmenopausal pelvic masses. Gynecol Oncol. 1994;54(2):117–123.
   Web of Science ®Google Scholar
• Bouzari Z, Yazdani S, Ahmadi MH, et al. Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Res Notes. 2011;4:206.
   PubMedGoogle Scholar
• Li AJ. New biomarkers for ovarian cancer: OVA-1 and ROMA in diagnosis. Int J Gynecol Cancer. 2012;22 Suppl 1:S5–S8.
   Google Scholar
• Zurawski VR, Knapp RC, Einhorn N, et al. An initial analysis of preoperative serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30(1):7–14.
   Web of Science ®Google Scholar
• Tanyi JL, Scholler N. Oncology biomarkers for gynecologic malignancies. Front Biosci (Elite Ed). 2012;4:1097–1110.
   Google Scholar
• Petignat P, Joris F, Obrist R. How CA125 is used in routine clinical practice. Eur J Cancer. 2000;36(15):1933–1937.
   Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–2303.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922–929.
   PubMedGoogle Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996;103(8):826–831.
   PubMedGoogle Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448–452.
   PubMed Web of Science ®Google Scholar
• Morgante G, la Marca A, Ditto A, De Leo V Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol. 1999;106(6):524–527.
   Google Scholar
• Aslam N, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG. 2000;107(11):1347–1353.
   Google Scholar
• Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009;113(2 Pt 1):384–394.
   PubMed Web of Science ®Google Scholar
• Hâkansson F, Hogdall EV, Nedergaard L, et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass. Acta Obstet Gynecol Scand. 2012;91(4):496–502.
   Web of Science ®Google Scholar
• van den Akker PA, Aalders AL, Snijders MP, et al. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecol Oncol. 2010;116(3):384–388.
   PubMed Web of Science ®Google Scholar
• Torres JC, Derchain SF, Faundes A, Gontijo RC, Martinez EZ, Andrade LA. Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer. Sao Paulo Med J. 2002;120(3):72–76.
   Google Scholar
• Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe AT, Beckmann MW. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res. 2009;35(1):131–138.
   Web of Science ®Google Scholar
• Raza A, Mould T, Wilson M, Burnell M, Bernhardt L. Increasing the effectiveness of referral of ovarian masses from cancer unit to cancer center by using a higher referral value of the risk of malignancy index. Int J Gynecol Cancer. 2010;20(4):552–554.
   PubMed Web of Science ®Google Scholar
• Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238(2):375–385.
   PubMed Web of Science ®Google Scholar
• Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402–408.
   PubMed Web of Science ®Google Scholar
• Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205(4):358. e1-e6.
   Web of Science ®Google Scholar
• Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P HE4–a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol. 2011;32(6):605–610.
   Web of Science ®Google Scholar
• Karlsen MA, Sandhu N, Høgdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127(2):379–383.
   PubMed Web of Science ®Google Scholar
• Allard J. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. J Clin Oncol. 2009;26 Suppl:abstr 5535.
   Google Scholar
• Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(3):228. el-e6.
   Web of Science ®Google Scholar
• Lenhard M, Stieber P, Hertlein L, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49(12):2081–2088.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Danese E, Ruzzenente O, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49(3):521–525.
   PubMed Web of Science ®Google Scholar
• Kadija S, Stefanovic A, Jeremic K, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22(2):238–244.
   Web of Science ®Google Scholar
• Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32(6):1087–1095.
   PubMed Web of Science ®Google Scholar
• Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121(3):487–491.
   PubMed Web of Science ®Google Scholar
• Zhang Z. An in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: harvesting the power of multiple biomarkers. Rev Obstet Gynecol. 2012;5(1):35–41.
   PubMedGoogle Scholar
• Muller CY. Doctor, should I get this new ovarian cancer test-OVA-1? Obstet Gynecol. 2010;116(2 Pt 1):246–247.
   Web of Science ®Google Scholar
• Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117(6):1289–1297.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2012;pii:S0090–8258(12)00888–00888.
   Web of Science ®Google Scholar
• Ware Miller R, Smith A, DeSimone CP, et al. Performance of the American College of Obstetricians and Gynecologists’ ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011;117(6):1298–1306.
   PubMed Web of Science ®Google Scholar